Skip to main content

New Products

  • Aurobindo Pharma's ANDA of olanzapine orally disintegrating tablets approved

    HYDERABAD, India — Aurobindo Pharma on May 15 gained approval to produce a generic version of olanzapine orally disintegrating tablets in 5-mg, 10-mg, 15-mg and 20-mg strengths. The drug is the generic version of Zyprexa Zydis tablets from Eli Lilly.

    The drug is used for the treatment of schizophrenia or bipolar I disorder. 

    Olanzapine orally disintegrating tablets had U.S. sales of $120.8 million for the 12 months ended March 31, according to IMS Health.

  • Pfizer launches 'Purple Pill' Nexium 24HR onto OTC shelves

    NEW YORK — Pfizer on Tuesday announced the introduction in the United States of over-the-counter Nexium 24HR, making the "Purple Pill" available for the treatment of frequent heartburn in adults. 

  • Solara Labs launches BariMelts line of supplements for Bariatric surgery patients

    MIAMI — Solara Labs on Tuesday announced the launch of its BariMelts line of dietary supplements produced for bariatric surgery patients.

    "The enhanced nutrient availability of BariMelts provides patients with a new option for getting the supplemental nutrition so important to their long-term success following bariatric surgery," said J. Rocca, CEO Solara Labs. 

  • Vapor Corp. introduces new e-liquids

    DANIA BEACH, Fla. — Vapor Corp., U.S.-based electronic cigarette company with brands that include Krave, VaporX, Hookah Stix and Fifty-One, earlier this week announced the launch of a new line of e-liquids for electronic vaporizers and other e-vaping devices. The line's debut is a resonse to the rapidly growing e-cigarette-vaporizer industry nationwide, the company said.

  • Dalvance receives FDA approval

    SILVER SPRING, Md. — The Food and Drug Administration on Friday approved Dalvance (dalbavancin), a new antibacterial drug used to treat adults with acute bacterial skin and skin structure infections, such as staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and streptococcus pyogenes.

  • Omnis Health launches the blood-glucose meter EmbraceEVO

    NASHVILLE, Tenn. — Omnis Health recently announced the launch of EmbraceEVO, a new blood-glucose meter.

    “The EmbraceEVO meter and test strips are positioned to provide end-users with an affordable cash-pay option that, in many cases, would be less than a co-pay through Medicare or third-party commercial insurance," said Rob Burton, president of Omnis Health.

  • Mars Chocolate announces decadent new treats

    HACKETTSTOWN, N.J. — Mars Chocolate has announced a slew of new products, which range from Mars Bites to Dove Whole Fruit Dipped in Dark Chocolate.

    Mars Bites give consumers a taste of their favorite candy bars in bite-size pieces. Mars is adding Twix, Musketeers and Milky Way bites to the portfolio. The suggested retail price is $1.49 for a 2.83-oz. sharing size. A 6-oz. stand up pouch is available for a SRP of $2.99.

  • Teva receives FDA nod for QVAR

    JERUSALEM — Teva Pharmaceutical on Friday announced that the Food and Drug Administration approved the use of QVAR (beclomethasone dipropionate HFA) with a dose counter for the treatment of asthma in patients 5 years of age and older.

    The counter will help asthma patients and their caregivers keep track of the number of remaining doses in the canister. It will be commercially available later this year, according to the company.

X
This ad will auto-close in 10 seconds